Dr Ravin Ratan on Advancing Sarcoma Care at ASCO 2024

In this interview ahead of the 2024 American Society of Clinical Oncology annual meeting (ASCO), Ravin Ratan, MD, MEd, The University of Texas MD Anderson Cancer Center, discusses study data he is excited to hear more about on the combination of trabectedin and low-dose irinotecan for relapsed/refractory Ewing sarcoma.

Related Keywords

Texas ,United States ,Mccormick Place ,Illinois ,Chicago ,American , ,Department Of Sarcoma Medical Oncology ,American Society Of Clinical Oncology ,University Of Texas Md Anderson Cancer Center ,Division Of Cancer Medicine ,Orthopaedic Center ,Clinical Oncology ,Sarcoma Oral Abstract Session ,American Journal ,Ravin Ratan ,Sarcoma Medical Oncology ,Cancer Medicine ,Cancer Center ,